Search research articles
Contact Us
Filters
Showing results (951-960 of 973) with videos related to
Page
of 98
Sort By:
Scientific Reports
|
November 9, 2023
Expanding our view of the cold-water coral niche and accounting of the ecosystem services of the reef habitat
Erik E Cordes, Amanda W J Demopoulos, Andrew J Davies, et al.
The Lancet. Oncology
|
January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Mark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
October 26, 2016
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience
Jordan M Cloyd, Matthew H G Katz, Laura Prakash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2024
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial
Ethan B Ludmir, Alexander D Sherry, Bryan M Fellman, et al.
The Lancet. Oncology
|
December 1, 2023
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial
Cullen M Taniguchi, Jessica M Frakes, Todd A Aguilera, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 9, 2012
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines
Margaret A Tempero, J Pablo Arnoletti, Stephen W Behrman, et al.
Journal of Nephrology
|
January 30, 2025
The impact of a secondary, rare, non-pathogenic PKD1 variant on disease progression in autosomal dominant polycystic kidney disease
Elhussein A E Elhassan, Kane E Collins, Sophia Heneghan, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success
Jeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Cancer Cell
|
August 29, 2025
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF<sup>V600E</sup> metastatic colorectal cancer
Van K Morris, Christine M Parseghian, Vahid Bahrambeigi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 14, 2019
Pancreatic Adenocarcinoma, Version 1.2019
Margaret A Tempero, Mokenge P Malafa, E Gabriela Chiorean, et al.
Page
of 98
Search research articles
Search
Showing results (951-960 of 973) with videos related to
Sort By:
Page
of 98
Scientific Reports
|
November 9, 2023
Expanding our view of the cold-water coral niche and accounting of the ecosystem services of the reef habitat
Erik E Cordes, Amanda W J Demopoulos, Andrew J Davies, et al.
The Lancet. Oncology
|
January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Mark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
October 26, 2016
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience
Jordan M Cloyd, Matthew H G Katz, Laura Prakash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2024
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial
Ethan B Ludmir, Alexander D Sherry, Bryan M Fellman, et al.
The Lancet. Oncology
|
December 1, 2023
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial
Cullen M Taniguchi, Jessica M Frakes, Todd A Aguilera, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 9, 2012
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines
Margaret A Tempero, J Pablo Arnoletti, Stephen W Behrman, et al.
Journal of Nephrology
|
January 30, 2025
The impact of a secondary, rare, non-pathogenic PKD1 variant on disease progression in autosomal dominant polycystic kidney disease
Elhussein A E Elhassan, Kane E Collins, Sophia Heneghan, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success
Jeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Cancer Cell
|
August 29, 2025
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF<sup>V600E</sup> metastatic colorectal cancer
Van K Morris, Christine M Parseghian, Vahid Bahrambeigi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 14, 2019
Pancreatic Adenocarcinoma, Version 1.2019
Margaret A Tempero, Mokenge P Malafa, E Gabriela Chiorean, et al.
Page
of 98